top of page

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

About the study

NCT Trial Number

NCT04123314

The drug being studied

Psilocybin

noun_Drug_2240951.png
noun_Institution_118530.png

Sponsored by

Johns Hopkins University

noun_date_3237048.png

Trial Start Date

Aug-20

noun_capsule_138144.png

About the participants

Age seeking

18 Years and older

gender

All

noun_Mental Health_2683241.png

Primary condition of volunteers accepted

Depression

noun_square_138133.png

Accepts healthy volunteers?

No

This study explores whether psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

Eyes Graffiti

Locations

United States, Maryland
Behavioral Pharmacology Research Unit
Baltimore, Maryland, United States, 21224

Contact: Hillary Jackson
410-550-5466
hjacks18@jhmi.edu

​

​

​

​

Get in contact

Find a study site convenient for you below, then email yourself the contact details and next steps

bottom of page